B7-H3 Antibody
- Known as:
- B7-H3 Antibody
- Catalog number:
- amm00012
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- B7-H3 Antibody
Related genes to: B7-H3 Antibody
- Gene:
- CD276 NIH gene
- Name:
- CD276 molecule
- Previous symbol:
- -
- Synonyms:
- B7-H3, B7H3, B7RP-2
- Chromosome:
- 15q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2005-03-04
- Date modifiied:
- 2016-10-05
Related products to: B7-H3 Antibody
Related articles to: B7-H3 Antibody
- Colorectal cancer (CRC) is the second leading cause of cancer-related death. The tumor immune microenvironment plays a critical role in tumor progression and immune evasion. B7-H3 (CD276), a member of the B7 family of immune checkpoint molecules, is frequently overexpressed in a variety of malignancies, including CRC. A systematic search of the literature was performed to identify studies evaluating B7-H3 in CRC. Data were extracted on study characteristics, B7-H3 expression and detection methods, molecular and signaling pathways, and clinical outcomes. Study quality and risk of bias were assessed using the MASTER scale, and findings were synthesized using a structured narrative approach. Sixty-three studies were included. B7-H3 expression was commonly reported but demonstrated substantial variability, largely driven by differences in detection and scoring methodologies. Preclinical evidence suggests that B7-H3 may contribute to tumor growth, invasion, immune evasion, and resistance to radio- and chemotherapy, potentially through pathways such as PI3K-AKT-mTOR, JAK-STAT, MAPK/ERK, NF-κB, VEGF/hypoxia, and Wnt/β-catenin. Preclinical studies have demonstrated that targeting B7-H3 may improve radiotherapy response and reduce metastatic burden in murine CRC models. However, these findings should be considered preliminary and are not yet supported by clinical evidence in humans. B7-H3 targeting remains an emerging therapeutic approach that requires further clinical validation. However, significant methodological heterogeneity in detection and scoring limits comparability across studies and precludes definitive conclusions regarding its clinical utility. B7-H3 should therefore be considered a candidate biomarker and further standardized. Prospective studies are needed to clarify its diagnostic, prognostic, and therapeutic relevance in CRC. - Source: PubMed
Publication date: 2026/08/13
Alwisi NouranHamid MohammadGhith DahabAlshare SalamAdham LujainSami SamihaBabu Giridhara RathnaiahVranić Semir - Glioblastoma (GBM), the most prevalent and aggressive malignant tumor of the nervous system, presents a formidable clinical challenge due to its rapid progression and extremely poor prognosis. T cell receptor fusion constructs (TRuC) -T cells represent a highly promising engineered T-cell therapy beyond CAR-T technology. Early prediction of TRuC-T cell cytotoxicity against GBM is crucial for clinical application. - Source: PubMed
Publication date: 2026/07/30
Lin JunyueZhang PeiyuanLi XinyuLu ShanhongYu QianjinZheng JiahaoYang JingChen XuanhaoWei ChengGao JiminZhao Ai - To determine whether immunohistochemical B7-H3 expression is associated with magnetic resonance imaging (MRI)-derived tumour volume, peritumoral brain oedema volume, and oedema index in adult gliomas. - Source: PubMed
Publication date: 2026/08/07
Juković-Bihorac FatimaBegagić EmirĐuričić SlavišaEfendić AlmaVranić Semir - Esophageal carcinoma (ESCA) remains highly lethal and lacks robust biomarkers for early detection and risk stratification. High mobility group box 3 (HMGB3) has been implicated as an oncogene in several cancers, but its role in ESCA has not been fully defined. To address these clinical and biological gaps, this study systematically characterized the expression profile, diagnostic and prognostic value, biological functions, and immune-related features of HMGB3 in ESCA through integrative bioinformatics analyses and validation. - Source: PubMed
Publication date: 2026/06/24
Fu Shen-BoJin LongLiu JiaYang RongLiang JingGuo Jun-JunChen LiZhao Bin - Mesothelioma is a rare, aggressive malignancy with poor prognosis. B7-H3 (CD276), an immune checkpoint molecule, and CD163-positive tumor-associated macrophages (TAMs) contribute to tumor progression and immune evasion. This study evaluated the prognostic impact of B7-H3 expression and CD163-positive TAM infiltration. This single-center retrospective study included 94 patients diagnosed with malignant mesothelioma between 2011 and 2024. B7-H3 expression was assessed using the H-score method and dichotomized at the cohort median. CD163-positive TAM density was quantified in hotspot high-power fields. Overall survival (OS) was analyzed using Kaplan-Meier, log-rank, and multivariable Cox regression analyses. Median OS was 10.15 months (IQR: 4.88-19.66). High B7-H3 expression was associated with shorter OS, whereas high CD163-positive TAM density was associated with longer OS. In multivariable analysis, B7-H3 expression, CD163 expression, tumor localization, recurrence status, and treatment status were independently associated with overall survival. Combined biomarker analysis showed the worst OS in the CD163-low/B7-H3-high group and the best OS in the CD163-high/B7-H3-low group. High B7-H3 expression was independently associated with shorter overall survival, whereas high CD163-positive TAM infiltration was associated with longer overall survival in this cohort. The combined B7-H3/CD163 profile may identify distinct prognostic subgroups and highlights the tumor immune microenvironment. - Source: PubMed
Publication date: 2026/08/03
Koç TülayYüceer Ramazan OğuzAltay TuncayTaş NeslihanÇelikgün Serkan